Abstract

Topical cidofovir gel applied once daily is more effective than placebo for acyclovir-resistant herpes simplex virus (HSV) disease. Therapy for acyclovir-resistant HSV infection continues to be unsatisfactory, with intravenous foscarnet the only reliably active treatment. Topical trifluridine is effective against small lesions but must be applied frequently and is difficult to apply evenly to mucocutaneous lesions. Given the …

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call